Blog

Interesting Study Reveals Possible Link Between Vitamin D and Autism


A recent study at the Children’s Hospital Oakland Research Institute (CHORI) investigated the effect that Vitamin D may have on social behavior associated with autism.  This research demonstrated that three hormones in the brain that affect social behavior: serotonin, oxytocin, and vasopressin are activated by the vitamin D hormone. In fact, researchers discovered that vitamin D has several vital roles and may be necessary for the production of serotonin in the brain. The results of this study further revealed that Vitamin D, tryptophan, and omega 3 fatty acids supplementation could potentially lift serotonin levels in the brain enough to relieve some of the symptoms without side effects.  Learn More

image above from: www.sciencedaily.com

Related Kits: 

Vitamin D ELISA Assay Kit

50 Examples: Saying "Thank You" To Your Facebook Fans


Eagle Biosciences is pleased to announce reaching a new social media milestone of reaching 1,000 likes on our Facebook page! We would like to sincerely thank all of our followers, new and old, for helping us get there. We truly appreciate your continued engagement and support. Eagle Biosciences promises to continue to bring you interesting posts, new research, and more!



Find us on:

Facebook: www.facebook.com/Eaglebioscience

Twitter:      www.twitter.com/Eaglebioscience




image above from www.viralblog.com

New Hormone Discovery:  Could it Lead to Ground Breaking Therapy for Type 2 Diabetes?


 

A recent study revealed
that researchers and Scientists at University of Southern
California Leonard Davis School of Gerontology have made an amazing
discovery of a new hormone, Mitochondrial-Derived
Peptide( a.k.a. MOTS-c).
This hormone has been found to
mimic the effects of exercise in that it has proven to combat weight gain
caused by a high fat diet and to balance metabolism. The mechanism of
action for hormone involves triggering a physiological responsein
muscle tissue which is the prime location of insulin sensitivity restoration
thereby normalizing or counteracting diet-induced
and age-dependent insulin resistance.

The effects of MOTS-c has been
tested in mice by injecting mice that had been fed a high fat diet with this
hormone and researchers concluded that this study was very successful. In
fact, the results revealed that not only had this hormone suppressed the
effects of a high fat diet such as growing obese and developing insulin
resistance, it also reversed age-dependent insulin resistance.

This study certainly brings
hope for age-dependent diseases such as diabetes but potentially a whole host
of other disease/conditions as well. The discovery of MOTS-c is a major
advance in the identification and search for a new target for therapy and
treatments.
Learn More

 

 

 

 

Related Kits:

Insulin ELISA Assay Kit

Insulin Ultrasensitive ELISA Assay Kit

IAA (Insulin Autoantibodies) ELISA Assay Kit

Endocrine Assay Kits

 

EagleBio’s March Promotions

 

Check Out our Monthly Promotions! 

30% Discount on Select Cardiac Biomarker Assays


BNP Fragment ELISA

NT-proCNP ELISA

NT-proANP ELISA

Endostatin ELISA

Big Endothelin-1 ELISA

Endothelin (1-21) ELISA

 

This promotion is good through the end of March just use the code below when ordering. 

PROMOTIONAL CODE: CARD0230 

 

 

Related News:

EagleBio Spotlight: Endothelin

EagleBio Spotlight: Natriuretic Peptides

EagleBio Spotlight: ANP

EagleBio Spotlight: CNP

EagleBio Spotlight: BNP

Interesting Study Highlighting Eagle Biosciences’ BNP Fragment ELISA Assay Kit 

EagleBio Spotlight: Endostatin

Eagle Biosciences Introduces Endothelin 1-21 and Big Endothelin-1 ELISA Kit

 

 

Related Resources Citing EagleBio Kits:

Stanek, B. et al. “Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction” Journal of American Cardiology 2001; 38: 436-442.

 

Related kits:

Cardiovascular Assay Kits

 

EagleBio Spotlight: Endothelin

 

What
are Endothelins?

Endothelins are a family of peptides, which comprises endothelin-1
(ET-1), endothelin-2 (ET-2) and endothelin-3 (ET-3), each containing 21
amino-acids.Endothelins were
discovered in 1988 when isolated from porcine aortic endothelial cells. They are long-acting vasoconstrictor substances
that play a strong, important role in blood pressure regulation and sodium and
fluid homeostasis. Other functions of
the ET system involve renal microcirculation regulation and they have been
found to contribute to the pathogenesis of renal injury.

The biological role of ET extends
beyond regulating vascular tone also in its growth regulatory properties. The
peptide interacts in an autocrine/paracrine manner with specific ET receptors
found on numerous cells, including smooth muscle cells, myocytes, and
fibroblasts. The half-life of ET in the
plasma is less than one minute, whereas clearance of Big ET is much slower,
therefore Big ET more accurately reflects the relative physiological effect.
Endothelin has been identified in a variety of tissues, including lung, kidney,
brain, pituitary and peripheral endocrine tissues and placenta.

Summary of Biological Functions:

Regulation of:

  • Blood pressure
  • Vascular tone
  • Sodium and fluid homeostasis
  • Renal microcirculation
  • Autocrine and paracrine functions

Why Measure Endothelins?

Since the principal actions of
endothelin surround increasing blood pressure and vascular tone, endothelin
antagonists may serve to play important parts in offsetting the negative impact
endothelin has in invivo. Past studies have focused on observing the mediation
of the pathogenesis of hypertension and its complications. More specifically,
some studies have demonstrated that ET-1 plays an significant role in the
progression of coronary artery disease(CAD) and subsequent plaque rupture and
ACS onset. In addition, findings from other studies have proven that Big ET-1
and ET-1 are strong independent predictors of survival in patients with severe
CHF. Based on this research, it is
believed that anti-endothelin therapy can help to improve symtoms and
potentially be used as treatment in such conditions as vascular remodelling,
left ventricular hypertrophy, hypertensive kidney damage and atherosclerosis. However, due to the complex nature of the
endothelin system, further research may be necessary to further define these
biological intricacies for the development of therapeutic agents. Robust, sensitive, and specific immunoassays
could be valuable tools to assist researchers in these investigations.

Biosynthesis
of Endothelins

The synthetic Endothelin pathway begins with a 212
amino acid peptide, called preproendothelin-1 which is then converted to
proendothelin-1 following a cleavage and removal of a short secretory
sequence. Furin (A protein that in
humans is encoded by the FURIN gene, its main function is to cleave proteins
just downstream of a basic amino acid target sequence) then prompts the
cleavage of proendothelin-1 to create biologically-inactive, 38 amino-acid
precursor called Big Endothelin. Big Endothelin-1
is then cleaved to yield endothelin-1 prompted by the action of several
endothelin-converting enzymes (ECE). Big Endothelin-1 can also be hydrolyzed by
chymase (serine proteases that have chymotrypsin-like cleavage properties) to
generate endothelin (1-21) in vitro.

What is Big Endothelin 1?

Big Endothelin-1 is a biologically-inactive
peptide and 38 amino-acid precursor with a plasma half-life of 30 minutes. Since
Plasma ET-1 has a much shorter half-life (about 1.5 min) and it has proven to
be problematic to measure circulating concentrations, Big Endothelin-1 has
become an excellent tool for measuring and monitoring the endothelin system
activation due to its inherent 
stability.

What is Endothelin 1-21?

Endothelin 1-21 is a potent vasoconstrictor and is created by the cleavage of Big Endothelin by a membrane-bound metalloproteinase, the Endothelin Converting Enzyme (ECE). This process yields active ET 1-21 and also the biological inactive C-terminal fragment (22-38) as described above.

Research and Indications:

The intrinsic biological function of Big ET-1 is
still under investigation as many aspects of its role are still unknown. However, recent studies suggest that this
analyte may work in opposition to ET-1 utilizing ET receptors and thereby
stimulating diueresis and natriuresis.
In fact, a very large study, Masson et al 2006 revealed
that ET stimulates the release of natriuretic peptides: ET participates in the
mechanical stretch-induced release of BNP by atrial myocytes. This research involved monitoring and
measuring various analytes with Big ET-1 serving as the main focus of study for
the cohort of 2,300 heart failure patients. This research also clearly
demonstrated that plasma concentrations of BNP show a strong and independent
association with Big ET using our Big Endothelin-1 ELISA Assay Kit.

In past studies, it has been
discovered that Big-Endothelin levels raise significantly in patients with
various types of tumors
and increased concentrations of this analyte have been
corrleated to worse outcomes. Teng et al 2006 investigated the levels of Big-Endothelin-1 in plasma of
gastric carinoma patients before and after radical gastroectomy utilizing our Big Endothelin-1 ELISA Assay Kit. It was evident from the results of this study
that there is a corrleation between the increase in Big ET-1 plasma levels and
the progression of tumors. Therefore, not
only could this analyte serve as a tumor marker for gastric cancer but it could
also serve as a powerful tool in monitoring recurrent disease.

Another
interesting study Arun et. al 2004 that utilized our Big Endothelin-1 ELISA Assay Kit, evaluated
the expression of Big ET-1 and ET-1 in non-small cell lung cancer (NSCLC). This was the first study to investigate this
analyte in this particular area of cancer research and more specifically, NSCLC. Since lung cancer is one of the most common
causes of cancer-related death in the Western world, there has been a great
need to further explore and understand the molecular biology of this
diseases. It discovered from the
results of this study that ET-1 and Big ET-1 are synthesized by NSCLC tumor in
vitro as well as in vivo and elevated levels have been associated with poor
outcomes. This evidenece has lead
invesigators to believe that ET-1 and Big ET-1 could serve as strong biomarkers
of this disease and as potential novel targets for treatment of NSCLC.

References:

  1. Agapitov, Alexei et al. “Role of Endothelin in Cardiovascular Disease.” JRAAS, 2002; 3:1-15.
  2. Arun, C. et al.  Endothelin-1 is a Novel Prognostic Factor in Non-Small Cell Lung Cancer.” Journal of Biological Markers 2004; 19 (4):262-267.
  3. Beneden, Van et al. “Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study.”J Card Fail. 2004 Dec; 10(6):490-5.
  4. Burg MM et al. “Depression Predicts Elevated Endothelin-1 in Patients With Coronary Artery Disease.” Psychosom Med 2011; 73: 2-6.
  5. Harrison-Benard, Lisa et al. “Enhanced Vascular Chymase-Dependent Conversion of Endothelin in the Diabetic Kidney.” The Oschner Journal 2013 13:1, 49-55.
  6. Jiao, Wenjie et al. “Elevation of circulating big endothelin-1: an independent prognostic factor for tumor recurrence and survival in patients with esophageal squamous cell carcinoma.” BMA Cancer 2008, 8:334.
  7. Masson et al. “The Prognostic Value of Big Endothelin-1 in More than 2,300 Patients with Heart Failure Enrolled in the Valsartan Heart Failure Trial (Val-HeFT).”Journal of Cardiac Failure 2006; 12: 375-380.
  8. Teng et al. “Pre- and Post-operative Plasma Big-Endothelin-1 Levels in Patients with Gastric Carcinoma Undergoing Radical Gastrectomy.” Anticancer Research 2006; 26: 2503-2508.
  9. Verghese, Mathew et al. “Clinical Implications of a Sandwich Enzyme Immunoassay for Big Endothelin-1.” Clinical Chemistry 1997; 43: 9-10. 

 

Related Kits:

Endothelin (1-21) ELISA Assay Kit

Big Endothelin-1 ELISA Assay Kit

Cardiovascular Assay Kits

 

 

Related News:

Eagle Biosciences Introduces Endothelin 1-21 and Big Endothelin-1 ELISA Kit

EagleBio Spotlight: Natriuretic Peptides

 

 

What
are Natriuretic peptides?

The natriuretic peptides belong to a family of
structurally similar but genetically different peptide hormones and include atrial, brain, and C type (ANP, BNP, and CNP, respectively). A-type and B-type have primarily have functions in the cardiovascular system and make up the cardiac natriuretic peptides. 
The discovery of this family was a major breakthrough in modern medicine and more specifically, cardiovascular physiology. This finding provided a direct connection between the heart and the kidneys with respect to the regulation of natriuresis.

These natriuretic peptides are modulated through their cognate receptors which are known as the ANP-A (a.k.a. NPR-A, GC-A), ANP-B (a.k.a. NPR-B, GC-B) and ANP-C (a.k.a NPR-C) receptors. ANP and BNP
preferentially bind to a membrane bound guanylyl cyclase (GC) receptor called
GC-A or NPR1, whereas CNP is the physiological ligand for GC-B (NPR2).

All natriuretic peptides are produced as propeptides,
which are then cleaved into the biologically active, C-terminal hormone
and the N-terminal fragment (NT-proANP 1-98, NT-proBNP 1-76 and NT-proCNP). It has been discovered that N-terminal fragments are
much more stable, and circulate in higher amounts than the active hormones. Thus, for these reasons the N-terminal fragments are easier and more reliable for measurement in serum or plasma.

The natriuretic peptides play an important role in the
regulation of cardiovascular and renal homeostasis and in the regulation of
fatty acid metabolism and body weight. In addition, in recent
studies natriuretic peptides have been proven to be valuable biomarkers for cardiac
pathology, including myocardial ischaemia and left ventricular dysfunction, as
well as risk stratification in congestive heart failure (CVD). 

Natriuretic peptides have a wide range of roles and
effects on several biological functions within the body as seen below.

 

Biological Functions of Natriuretic
peptides:

  • Natriuresis
  • Vasodilation
  • Homeostasis
  • Inhibition of
    aldosterone system
  • Inhibition of
    renin-angiotensin system
  • Inhibition of
    vascular smooth muscle growth (i.e. myocardial, endothelial, smooth
    muscle)
  • Inhibition of
    ADH hormone
  • Inhibition of
    aldosterone hormone

References

  1. Clerico A et al. “Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones.” Am J Physiol Heart Circ Physiol 2011; 301: H12-H20.
  2. Doust, Jenny et al. “The Role of BNP Testing in Heart Failure.” American Family Phyisician; 2006 Dec 1;74(11):1893-190.
  3. Lauridsen, Bo K et al. “ProANP Plasma Measurement Predicts All-Cause Mortality in Acutely Hospitalized Patients: A Cohort Study.” BMJ Open 2013;3:e003288 doi:10.1136/bmjopen-2013-003288
  4. Moro, Cedric et al. “Natriuretic Peptides: New Players in Energy Homeostasis.” Diabetes 2009; 12: 2726-2728
  5. Nazario, B et al. “Atrial and Brain Natriuretic Peptides Stimulate the Production and Secretion of C-type Natriuretic Peptide from Bovine Aortic Endothelial Cells.” Journal of Clinical Investigation 1995 Mar; 95(3): 1151–1157.
  6. Schreibe, Donald et al. “Natriuretic Peptides in Congestive Heart Failure.” Medscape 2012: Jan 10.
  7. Suzuki, T et al. “The Role of the Natriuretic Peptides in the Cardiovascular System.” Cardiovascular Research 2001; 51: 489–494.
  8. Stanek, B. et al. “Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction” Journal of American Cardiology 2001; 38: 436-442

Related Resources Citing EagleBio Kits:

  1. Stanek, B. et al. “Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction” Journal of American Cardiology 2001; 38: 436-442.

Related Kits:

proANP ELISA Assay Kit

BNP Fragment (Nt-proBNP 8-29) ELISA Assay Kit

NT-proCNP ELISA Assay Kit

Cardiovascular Assay Kits

 

Related News:

EagleBio Spotlight: ANP

EagleBio Spotlight: BNP

EagleBio Spotlight: CNP

Interesting Study Highlighting Eagle Biosciences’ BNP Fragment ELISA Assay Kit

Did you know that ticks have antifreeze proteins?  A recent study conducted by a Yale professor of medicine focused on ticks and their unique cold resistant properties. These antifreeze proteins are called IAFGP (Ixodes scapularis anti-freeze glycoprotein) and are activated in ticks in the winter and prevent their cells and tissues from freezing.  In fact, researchers have discovered that these proteins help to decrease the damage during frostbite, thus reducing or limiting the inflammatory cascade associated with cell death.  Mice that were utilized for this study demonstrated a clear resistance to exposure to extreme cold when specially bred with genes to produce IAFGP.  There is certainly an enormous amount of potential for such proteins in terms of numerous therapeutic applications.  Read More



 

What
is CNP?

CNP stands for C-type natriuretic peptide and it is
derived from a preprohormone of 126 amino acids and a prohormone of 53 amino
acids. CNP was originally found in the
central nervous system in much greater concentrations than ANP or BNP. CNP
is produced by cardiac tissue, but is expressed primarily in the brain,
pituitary gland, vascular endothelium, kidney and female reproductive tract. It
has been discovered that it is produced in the vascular endothelial cells and after
secretion of CNP from these endothelial cells, it is regulated by cytokines and
growth factors.

Unlike ANP and BNP, CNP has a very insignificant role
in natriuretic and diuretic processes. The
physiological role of CNP is not only studied in cardiac disease, but also in
bone developmental biology, bone research, renal diseases, embryonic
developmental research, and vascular diseases. In past studies, it has been
found to play an important paracrine regulatory role in the
vasculature and involvement in neural control.

 

Biochemical Structure of CNP:

CNP produces 22 and 53 amino acid fragments.
Unlike ANP and BNP, CNP terminates in the second cysteine residue, lacking a
further C-terminal extension.

 

What is NTproCNP?

NT-proCNP is the amino-terminal peptide derived from the cleavage of the prohormone proCNP. It is an equimolar product of CNP biosynthesis and is easily measured in plasma. NTproCNP is not subject to clearance pathways and it is found in the circulation at 20- to 50-fold higher concentrations than the biologically active forms of CNP. 

 

Why Measure NTproCNP?

NTproCNP is considered to be a reliable and stable marker for measuring
CNP biosysthesis. Studies have revealed
that there is a high serum CNP concentration in critically ill subjects or individuals
who have undergone trauma. NT-proCNP has
been correlated to biomarkers of organ dysfunction and has been associated with
inflammatory and metabolic pathways.
Therefore, it has been recently been proposed as a novel biomarker for
predicting sepsis in traumatized patients.

 

 Indications for CNP:

  • Vascular Disease
  • Diabetes
  • Skeletal Development
  • Sepsis
  • Renal Disease

 

References:

  1. Clerico A et al. “Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones.” Am J Physiol Heart Circ Physiol 2011; 301: H12-H20.
  2. Hoffman et al. “Prognostic Value of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Patients With Severe Sepsis.” Circulation; 2005:112:527-534.
  3. Koch, A. et al. “Prognostic value of circulating amino-terminal pro-C-type natriuretic peptide in critically ill patients.” Critical Care 2011, 15:R45 doi:10.1186/cc10007.
  4. Moro, Cedric et al. “Natriuretic Peptides: New Players in Energy Homeostasis.” Diabetes 2009; 12: 2726-2728
  5. Nazario, B et al. “Atrial and Brain Natriuretic Peptides Stimulate the Production and Secretion of C-type Natriuretic Peptide from Bovine Aortic Endothelial Cells.” Journal of Clinical Investigation 1995 Mar; 95(3): 1151–1157. 
  6. Olney, Robert et al. “Amino-terminal propeptide of C-type natriuretic peptide (NTproCNP) predicts height velocity in healthy children.” Clin Endocrinol (Oxf). 2012 Sep; 77(3): 416–422.
  7. Schreibe, Donald et al. “Natriuretic Peptides in Congestive Heart Failure.” Medscape 2012: Jan 10.
  8. Suzuki, T et al. “The Role of the Natriuretic Peptides in the Cardiovascular System.” Cardiovascular Research 2001; 51: 489–494.

 

 

Related Resources Citing EagleBio Kits:

          1. Stanek, B. et al. “Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction” Journal of American Cardiology 2001; 38: 436-442.

Related Kits:

NT-proCNP ELISA Assay Kit

proANP ELISA Assay Kit

BNP Fragment (Nt-proBNP 8-29) ELISA Assay Kit

Cardiovascular Assay Kits

 

Related News:

EagleBio Spotlight: Natriuretic Peptides

EagleBio Spotlight: ANP

EagleBio Spotlight: BNP

Interesting Study Highlighting Eagle Biosciences’ BNP Fragment ELISA Assay Kit

EagleBio Spotlight: ANP

 

What
is ANP?

The first
natriuretic peptide was identified in 1983 and named atrial natriuretic peptide
(ANP). ANP is a 28-amino acid polypeptide resulting from the C-terminal end of
the prohormone proANP. It is largely produced in the cardiac atria, and ANP is
quickly secreted in response to atrial stretching. ANP has the following
physiological effects:

  • Increases glomerular
    filtration rate by dilating afferent arterioles
  • Inhibits the collecting ducts from reabsorbing sodium,
    both directly and indirectly (by inhibiting aldosterone secretion)
  • Inhibits release of renin

The renin-angiotensin system and ANP
function antagonistically in the maintenance of fluid/electrolyte balance and
blood pressure.

Normal hearts
secrete extremely small amounts of ANP, but elevated levels are found in
patients with left ventricular (LV) hypertrophy and mitral valve disease.

 

Biochemical structure of ANP:

ANP is synthesized as a 126 amino acidprecursor protein which is cleaved to produce a
96 aminoacid amino-terminal fragment and a 28 amino acid
carboxyl-terminal fragment. The carboxyl-terminal 28 amino acid fragment is the biologically active peptide and
has shorter half-life than the amino-terminal fragment.

 

 

Conserved residues are shaded and the line
within the ring represents the disulfide bond. 

 

What
is proANP?

ProANP is the prohormone of ANP (ANP is stored as a
126–amino acid prohormone (proANP1–126)). After this prohormone is released it is then cleaved into
 equimolar amounts of the biologically active C-terminal peptide (ANP (99–126)) and the residual N-terminal peptide (NT-proANP (1–98)) in response to atrial wall stretch.

α-ANP has a half-life of 3-4 minutes thus is quickly cleared from circulation. ProANP (1-98) on the other hand, has a significantly longer half-life of 60-120 minutes leading to much higher concentrations in blood as compared to α-ANP. 

 

Why Measure proANP (1-98)?

Atrial natriuretic peptide (ANP) has an important physiological roles in fluid homeostasis and cardiac pathology. The longer half life of proANP (1-98) offers advantages for measuring  the ANP in the blood over α-ANP due to its lack of sensitivity to the pulsatile secretion of ANP. In fact,proANP (1-98) may provide better insight to the ANP status and its chronic secretion in the blood. Studies have shown that proANP serves as a
valuable and stable marker for several areas of research ranging from sepsis to
predicting and aiding in risk stratification for heart failure.

 

Diseases/conditions associated with increased ANP levels:

  • Diabetes and Obesity
  • Renal Disease/Renal dysfunction
  • Hypertension
  • Pneumonia
  • Asthma attacks
  • Recent heart attack
  • Heart failure/Cardiac impairment
  • Cardiomyopathy
  • Sepsis
  • Sleep apnea

 

References:

  1. Haviv, M. et al. “Atrial Natriuretic Peptidein Children with Pneumonia.” Pediatric Pulmonology 40:306–309(2005).
  2. Hoffman et al. “Prognostic Value of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Patients With Severe Sepsis.” Circulation; 2005:112:527-534. 
  3. Lauridsen, Bo K et al. “ProANP Plasma Measurement Predicts All-Cause Mortality in Acutely Hospitalized Patients: A Cohort Study.” BMJ Open 2013;3:e003288 doi:10.1136/bmjopen-2013-003288.
  4. Moro, Cedric et al. “Natriuretic Peptides: New Players in Energy Homeostasis.” Diabetes 2009; 12: 2726-2728. 
  5. Robichaud, A. et al. “Plasma Atrial Natriuretic Peptide During Spontaneous Bronchoconstriction in Asthmatics. Peptides 1995;16(4):653-6.

  6. Suzuki, T et al. “The Role of the Natriuretic Peptides in the Cardiovascular System.” Cardiovascular Research 2001; 51: 489–494. 

 

 

 

Related Resources Citing EagleBio Kits:

  1. Stanek, B. et al. “Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction” Journal of American Cardiology 2001; 38: 436-442.

 

Related Kits:

proANP ELISA Assay Kit

Cardiovascular Assay Kits

Related News:

EagleBio Spotlight: Natriuretic Peptides

EagleBio Spotlight: BNP

EagleBio Spotlight: CNP

Interesting Study Highlighting Eagle Biosciences’ BNP Fragment ELISA Assay Kit